Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs Insulin Degludec in Type 2 Diabetes (SURPASS-3)
NCT03882970Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03882970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882970.